Medindia

X

Glenmark India Launches Teneligliptin for Management of Type 2 Diabetes

by Dr. Trupti Shirole on  July 24, 2015 at 1:21 AM Drug News   - G J E 4
International Diabetes Federation's (IDF) metrics suggest that there were 66.8 million diabetes patients in India in 2014 who will rise to 110 million patients by 2035. According to the Associated Chambers of Commerce and Industry (Assocham), approximately 26.5% of Bengaluru's adult population is diabetic. Glenmark Pharmaceuticals Limited on Wednesday launched its advanced diabetes treatment molecule Teneligliptin under the brands Ziten and Zita plus, priced at Rs. 19.90 per tablet.
 Glenmark India Launches Teneligliptin for Management of Type 2 Diabetes
Glenmark India Launches Teneligliptin for Management of Type 2 Diabetes
Advertisement

Sujesh Vasudevan, head, India business, Glenmark, said, "Glenmark is proud to be the first player to introduce Teneligliptin, an advanced form of treatment for diabetes at a significantly affordable cost. Through this we will be playing a major role in making anti-diabetes treatment more effective and affordable for millions of patients across the country."

Advertisement
Teneligliptin is an advanced new third-generation oral anti-diabetic agent employed for the management of type 2 diabetes which is effective in suppressing glucagon release and increasing insulin to subsequently lower blood glucose levels. Other gliptin medicine brands include Januvia 100 mg and Istavel 100 mg priced at Rs. 45, and Vysov 50 mg, Trajenta 5 mg, Galvus 50 mg, Jalra 50 mg and Zomelis 50 mg, all priced at Rs. 42.70.

Vasudevan said, "Ziten and Zita Plus help patients save approximately Rs. 9,000 per year, as much as 55%, compared to other brands which cost between Rs. 15,000 to Rs. 16,000 per year for treatment. Ziten and Zita Plus cost Rs. 7,263 per year. Glenmark's diabetes business is valued around Rs. 100 crore and the entire diabetes treatment market of India is valued at Rs. 6,600 crore. Glenmark's diabetes business is clocking a growth rate of 20% year-on-year."

Source: IANS
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All